Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree!
I’m buying. Stop spreading untrue story. Link about White House lies?
Interesting... Thanks!
Q3 Revenue Predictions:
$10,000,001
You have been wrong more than right, but I think you’ll be right this time. Best of luck to all of us LONGS!!!
We can agree on that.
They are trying really hard to hold it down. We will be up eventually, NO WORRY!!!
It’s up again, It’s down again...Oops it’s up again!!! LOL LOL LOL LOL !!!
02-04-2021
While the market’s reaction was unequivocally negative, B. Riley analyst Mayank Mamtani looks on the bright side.
“We remain intrigued with the unequivocally robust benefit noted on T cell responses, including relative to its in-class peers in the form of adenoviral vector-based C-19 vaccine candidates, particularly as it relates to the potential role in demonstrating long-lasting cross reactive immunity,” the 5-star analyst said. “In addition, we are also encouraged by safety profiles with no serious AEs noted to date and a very low event rate of solicited GI symptoms with a majority of events noted on high doses and generally reported as mild and transient.”
Mamtani also says Merck’s recent discontinuation of its own oral VSV-platform based vaccine candidate was “likely safety-related.” This implies VXRT's data having “favorable readthrough to the broader platform as well as VXRT's dose optimization efforts.”
Vaxart’s offering has several advantages. One being its tablet form, which could appeal to needle-shy people. It is also stable at room temperature, compared to the EUA approved vaccines’ cold storage requirements. To this end, Vaxart said it plans to advance its Covid-19 vaccine program into a Phase 2 study.
All in all, Mamtani remains behind VXRT, and sticks to his Buy rating. The $16 price target remains, as well, suggesting upside of 78% from current levels. (To watch Mamtani’s track record, click here)
Vaxart has only 2 other recent reviews, but both agree with Mamtani’s assessment. The 2 additional Buys add up to a Strong Buy consensus rating. The average price target is an optimistic one, and at $17.67, implies gains of 96% could be in the cards over the next 12 months. (See VXRT stock analysis on TipRanks)
Your claim is so ridiculous when most of their developments are in phase 1 and phase 2. Your statement does not prove it’s a scam...LOL LOL!!!
Volume is picking up the last several days. Expecting good Q...
Maybe it’s not a SCAM? Shorts call every companies they short a scam. Lol
Interesting explanation
Tucker Just Tweeted:
“Our founder and CSO, Sean Tucker, PhD, discussed how a vaccine that induces a strong T-cell response could potentially provide long-lasting protection against infection. Learn about our #COVID-19 #vaccine candidate’s unique immunogenicity profile here: bit.ly/3cLb5BU”
Nah, I doubt it even goes lower than $7 let alone $5. But one can always dream!!!
It’s tricky. Right after I just put a BID of 150,000 shares at .064, the NITE immediately moved its BID to 10,000 at .067 above me. LOL LOL!!!
Have more than 2.5 million shares, but still cheap at this price IMO.
I slapped 100000 at .07 and it took out .066, .068
I just slapped that for you.
LOL LOL it happens all the time with ELTP. Get use to it !!! Love me some more ELTP TODAY.
I still be believe in it’s science. Let’s see what Tucker says in the conference before I’m buying again.
VXRT’s technology is still good but they have to find the way to make it better than the ones went before it. Pills form is the best and it’s the future of all vaccines, but if the results are not as promising as others, it’s still useless pills.
Things are looking good for IBIO. Just sold my VXRT and added 20,000 shares of IBIO. Good luck!
You are making the right choice, IMO. This will go down further as MMS and shorts are in control at the moment. They always have when we have negative news. IMO good re-entry point will be $7-$8. Good luck!!!
Thanks gew59. It was a good ride.
I got I very low since March, if it drop back to that level I’m in again.
Phase 1 not successful. Sold most of mine. Good luck guys!
It’s fun to see HOD $25, but I wouldn’t sweat about it. With good news release tomorrow morning or during the conference, $30-50 is not hard to hit. Let’s hope and pray that we have good phase 1 results. I am very optimistic it will be a great PR. Good luck mick!
I’m not investing in KIN so I don’t really pay close attention to it. Good luck if you are!
I don’t know how to dance but I having 6 cold ones. Waiting for good news on phase 1 results and I’m good to hold for a long haul. Good luck to you and the rest of the gang here!!!
Yup. Maybe tomorrow. Who knows!!!
Maybe before close. $24.5 as I’m typing.
Late Monday or Tuesday morning. Conference is on Tuesday and they want to release before that... only option imo.
I got in fine. Try again
Good slapping and get others involved. NICE!
LOL and SMH. If you can see the data before anyone else, you must be insider. LOLx2!!!
Good to see the PPS is above .06 again. Let’s keep it rolling Kenny!!!
The HOLY GRAIL
Can be today AH or tomorrow or within this week...IMO
Isn’t that old news? LOL